CA 19-9

The CA 19-9 test measures the level of cancer antigen 19.9 in the blood. It is most commonly associated with conditions affecting the pancreas and biliary system and is used mainly in clinical monitoring.

Clinical indications
* Supporting the evaluation of pancreatic cancer
* Monitoring of cholangiocarcinoma
* Assessing response to treatment in pancreatic or biliary tract malignancies

The findings related to these particular clinical tests are a general guide and do not cover every possible scenario, this is because every patient is unique and these results only have true clinical significance when combined with the patient’s full medical history, a physical exam, and other diagnostic findings.

Phlebotomy service fee: £20.